A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab (VICTORION-LEAP)

July 14, 2026 updated by: Novartis Pharmaceuticals

Real-World Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab in Italy

This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.

Study Overview

Study Type

Observational

Enrollment (Estimated)

5995

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Novartis Pharmaceuticals

Study Locations

      • Basel, Switzerland, CH-4056
        • Recruiting
        • Novartis

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult patients in Italy who initiated inclisiran, evolocumab, or alirocumab treatment during the identification period with at least 18 months of follow-up.

Description

Inclusion criteria:

  • A first ever prescription of injection of inclisiran, evolocumab, or alirocumab during the identification period.
  • Age ≥18 years at index date.
  • With at least 12 months data availability prior to index date.

Exclusion criteria:

• Patients who received either evolocumab or alirocumab as their index study drug and who were dispensed the other anti-PCSK9-mAb (alirocumab and evolocumab respectively) before the identification period.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Inclisiran Cohort
Patients receiving inclisiran injection(s).
Evolocumab Cohort
Patients receiving evolocumab injection(s).
Alirocumab Cohort
Patients receiving alirocumab injection(s).
Pooled Anti-PCSK9-mAb Cohort
Patients receiving anti-PCSK9-mAbs either evolocumab or alirocumab.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of Days Covered (PDC) With Inclisiran
Time Frame: 6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months
PDC is defined as the number of days with medication supply (covered days) within a period of interest divided by the number of days in the period of interest. Index date is the date of first use of the treatment.
6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months
Annual PDC With Inclisiran
Time Frame: 0-12 months, 12-24 months, 24-48 months
PDC is defined as the number of days with medication supply (covered days) within a period of interest divided by the number of days in the period of interest.
0-12 months, 12-24 months, 24-48 months
Persistence With Inclisiran Treatment
Time Frame: 6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months
Persistence is defined as time to discontinuation by exceeding a pre-specified allowable gap beyond the scheduled time for the next dose/prescription. Index date is the date of first use of the treatment.
6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PDC With Anti-PCSK9-mAbs
Time Frame: 6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months
PDC is defined as the number of days with medication supply (covered days) within a period of interest divided by the number of days in the period of interest. Index date is the date of first use of the treatment.
6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months
Annual PDC With Anti-PCSK9-mAbs
Time Frame: 0-12 months, 12-24 months, 24-48 months
PDC is defined as the number of days with medication supply (covered days) within a period of interest divided by the number of days in the period of interest.
0-12 months, 12-24 months, 24-48 months
Persistence With Anti-PCSK9-mAb Treatment
Time Frame: 6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months
Persistence is defined as time to discontinuation by exceeding a pre-specified allowable gap beyond the scheduled time for the next dose/prescription. Index date is the date of first use of the treatment.
6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months
Baseline Demographics
Time Frame: Baseline
Baseline
Baseline Clinical Characteristics: Number of Patients by Diagnosis
Time Frame: Baseline
Diagnoses include primary hypercholesterolemia, mixed dyslipidemia, homozygous familial hypercholesterolemia, and atherosclerotic cardiovascular disease (ASCVD) where available.
Baseline
Baseline Clinical Characteristics: Number of Patients by Comorbidity
Time Frame: Baseline
Baseline
Baseline Clinical Characteristics: Charlson Comorbidity Index (CCI) Score
Time Frame: Baseline
CCI is a weighted index that takes into account both the number and the seriousness of comorbid diseases. It predicts the ten-year mortality for a patient who may have a range of comorbid conditions. CCI can be categorized as low (0-1) and high (≥2).
Baseline
PDC With Lipid Lowering Therapies (LLTs) at Baseline
Time Frame: Baseline
PDC is defined as the number of days with medication supply (covered days) within a period of interest divided by the number of days in the period of interest.
Baseline
Number of Patients by LLTs Received
Time Frame: Every 3 months from baseline through index date until the end of follow-up, assessed up to 48 months
Treatment patterns of LLT use. Index date is the date of first use of the treatment.
Every 3 months from baseline through index date until the end of follow-up, assessed up to 48 months
Number and Percentage of Patients Receiving Each of the Inclisiran Doses
Time Frame: From index date until the end of follow-up, assessed up to 48 months
Index date is the date of first use of the treatment.
From index date until the end of follow-up, assessed up to 48 months
Time Between Inclisiran Doses
Time Frame: From index date until the end of follow-up, assessed up to 48 months
Index date is the date of first use of the treatment.
From index date until the end of follow-up, assessed up to 48 months
Number of Anti-PCSK9-mAb Prescriptions
Time Frame: From index date until the end of follow-up, assessed up to 48 months
Index date is the date of first use of the treatment.
From index date until the end of follow-up, assessed up to 48 months
Time Between Anti-PCSK9-mAb Prescriptions
Time Frame: From index date until the end of follow-up, assessed up to 48 months
Index date is the date of first use of the treatment.
From index date until the end of follow-up, assessed up to 48 months
Association Between Treatment Adherence and Baseline Characteristics per Cohort
Time Frame: Baseline, up to 48 months
Multivariable regression models will be used to examine how baseline characteristics could be associated with treatment adherence per cohort. Baseline characteristics may include age, sex, diagnosis, cardiovascular events, comorbidities, adherence to LLTs, and number of medications received at index and post-index.
Baseline, up to 48 months
Association Between Treatment Persistence and Baseline Characteristics per Cohort
Time Frame: Baseline, up to 48 months
Cox proportional hazards models will be used to examine how baseline characteristics could be associated with treatment persistence per cohort. Baseline characteristics may include age, sex, diagnosis, cardiovascular events, comorbidities, adherence to LLTs, and number of medications received at index and post-index.
Baseline, up to 48 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 2, 2026

Primary Completion (Estimated)

October 30, 2026

Study Completion (Estimated)

October 30, 2026

Study Registration Dates

First Submitted

April 14, 2026

First Submitted That Met QC Criteria

April 14, 2026

First Posted (Actual)

April 22, 2026

Study Record Updates

Last Update Posted (Actual)

July 15, 2026

Last Update Submitted That Met QC Criteria

July 14, 2026

Last Verified

July 1, 2026

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe